Mogamulizumab Nips At Adcetris’s Heels In CTCL After New Results

Mogamulizumab has met its primary survival endpoint in a comparative Phase III trial in cutaneous T-cell lymphoma, positioning the Kyowa Hakko Kirin product as a potential close follower to Adcetris in the second-line setting.